The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics
The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2
family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic …
family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic …
Acquired resistance to TKIs in solid tumours: learning from lung cancer
The use of advanced molecular profiling to direct the use of targeted therapy, such as
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …
[HTML][HTML] Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
BA Chan, BGM Hughes - Translational lung cancer research, 2015 - ncbi.nlm.nih.gov
In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
D Planchard, TM Kim, J Mazieres, E Quoix… - The Lancet …, 2016 - thelancet.com
Summary Background Activating BRAF V600E (Val600Glu) mutations are found in about 1–
2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in …
2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in …
Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non–small-cell lung cancer
Purpose Approximately 1% to 2% of non–small-cell lung cancers (NSCLCs) harbor a c-ros
oncogene 1 (ROS1) rearrangement. Crizotinib, an inhibitor of anaplastic lymphoma kinase …
oncogene 1 (ROS1) rearrangement. Crizotinib, an inhibitor of anaplastic lymphoma kinase …
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
JJ Lin, VW Zhu, S Yoda, BY Yeap… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Advanced anaplastic lymphoma kinase (ALK) fusion-positive non–small-cell lung
cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs) …
cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs) …
TRKing down an old oncogene in a new era of targeted therapy
A Vaishnavi, AT Le, RC Doebele - Cancer discovery, 2015 - AACR
The use of high-throughput next-generation sequencing techniques in multiple tumor types
during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding …
during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding …
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Background ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK
tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably …
tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably …
Small cell lung cancer: where do we go from here?
Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately
14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed …
14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed …
A comprehensive review of protein kinase inhibitors for cancer therapy
R Kannaiyan, D Mahadevan - Expert review of anticancer therapy, 2018 - Taylor & Francis
Introduction: Protein kinases are involved in various cellular functions. About 2% of the
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …